Literature DB >> 21257910

Decreased stability and increased formation of soluble aggregates by immature superoxide dismutase do not account for disease severity in ALS.

Kenrick A Vassall1, Helen R Stubbs, Heather A Primmer, Ming Sze Tong, Sarah M Sullivan, Ryan Sobering, Saipraveen Srinivasan, Lee-Ann K Briere, Stanley D Dunn, Wilfredo Colón, Elizabeth M Meiering.   

Abstract

Protein aggregation is a hallmark of many diseases, including amyotrophic lateral sclerosis (ALS), where aggregation of Cu/Zn superoxide dismutase (SOD1) is implicated in causing neurodegeneration. Recent studies have suggested that destabilization and aggregation of the most immature form of SOD1, the disulfide-reduced, unmetallated (apo) protein is particularly important in causing ALS. We report herein in depth analyses of the effects of chemically and structurally diverse ALS-associated mutations on the stability and aggregation of reduced apo SOD1. In contrast with previous studies, we find that various reduced apo SOD1 mutants undergo highly reversible thermal denaturation with little aggregation, enabling quantitative thermodynamic stability analyses. In the absence of ALS-associated mutations, reduced apo SOD1 is marginally stable but predominantly folded. Mutations generally result in slight decreases to substantial increases in the fraction of unfolded protein. Calorimetry, ultracentrifugation, and light scattering show that all mutations enhance aggregation propensity, with the effects varying widely, from subtle increases in most cases, to pronounced formation of 40-100 nm soluble aggregates by A4V, a mutation that is associated with particularly short disease duration. Interestingly, although there is a correlation between observed aggregation and stability, there is minimal to no correlation between observed aggregation, predicted aggregation propensity, and disease characteristics. These findings suggest that reduced apo SOD1 does not play a dominant role in modulating disease. Rather, additional and/or multiple forms of SOD1 and additional biophysical and biological factors are needed to account for the toxicity of mutant SOD1 in ALS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21257910      PMCID: PMC3038722          DOI: 10.1073/pnas.0913021108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

1.  Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form.

Authors:  Aaron Kerman; Hsueh-Ning Liu; Sidney Croul; Juan Bilbao; Ekaterina Rogaeva; Lorne Zinman; Janice Robertson; Avijit Chakrabartty
Journal:  Acta Neuropathol       Date:  2010-01-29       Impact factor: 17.088

2.  BPPred: a Web-based computational tool for predicting biophysical parameters of proteins.

Authors:  Christian D Geierhaas; Adrian A Nickson; Kresten Lindorff-Larsen; Jane Clarke; Michele Vendruscolo
Journal:  Protein Sci       Date:  2006-11-22       Impact factor: 6.725

3.  Soluble misfolded subfractions of mutant superoxide dismutase-1s are enriched in spinal cords throughout life in murine ALS models.

Authors:  Per Zetterström; Heather G Stewart; Daniel Bergemalm; P Andreas Jonsson; Karin S Graffmo; Peter M Andersen; Thomas Brännström; Mikael Oliveberg; Stefan L Marklund
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-21       Impact factor: 11.205

Review 4.  Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS.

Authors:  Bradley J Turner; Kevin Talbot
Journal:  Prog Neurobiol       Date:  2008-01-16       Impact factor: 11.685

5.  Thiol compounds inhibit the formation of amyloid fibrils by beta 2-microglobulin at neutral pH.

Authors:  Kaori Yamamoto; Hisashi Yagi; Daisaku Ozawa; Kenji Sasahara; Hironobu Naiki; Yuji Goto
Journal:  J Mol Biol       Date:  2007-12-07       Impact factor: 5.469

6.  Cysteine 111 affects aggregation and cytotoxicity of mutant Cu,Zn-superoxide dismutase associated with familial amyotrophic lateral sclerosis.

Authors:  Mauro Cozzolino; Ilaria Amori; Maria Grazia Pesaresi; Alberto Ferri; Monica Nencini; Maria Teresa Carrì
Journal:  J Biol Chem       Date:  2007-11-15       Impact factor: 5.157

7.  Amyotrophic lateral sclerosis-associated copper/zinc superoxide dismutase mutations preferentially reduce the repulsive charge of the proteins.

Authors:  Erik Sandelin; Anna Nordlund; Peter M Andersen; Stefan S L Marklund; Mikael Oliveberg
Journal:  J Biol Chem       Date:  2007-05-18       Impact factor: 5.157

8.  A limited role for disulfide cross-linking in the aggregation of mutant SOD1 linked to familial amyotrophic lateral sclerosis.

Authors:  Celeste M Karch; David R Borchelt
Journal:  J Biol Chem       Date:  2008-03-03       Impact factor: 5.157

Review 9.  Protein misfolding and neurodegeneration.

Authors:  Claudio Soto; Lisbell D Estrada
Journal:  Arch Neurol       Date:  2008-02

10.  Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival.

Authors:  Qi Wang; Joshua L Johnson; Nathalie Y R Agar; Jeffrey N Agar
Journal:  PLoS Biol       Date:  2008-07-29       Impact factor: 8.029

View more
  43 in total

1.  The Disulfide Bond, but Not Zinc or Dimerization, Controls Initiation and Seeded Growth in Amyotrophic Lateral Sclerosis-linked Cu,Zn Superoxide Dismutase (SOD1) Fibrillation.

Authors:  Madhuri Chattopadhyay; Ekeoma Nwadibia; Cynthia D Strong; Edith Butler Gralla; Joan Selverstone Valentine; Julian P Whitelegge
Journal:  J Biol Chem       Date:  2015-10-28       Impact factor: 5.157

Review 2.  Superoxide dismutases and superoxide reductases.

Authors:  Yuewei Sheng; Isabel A Abreu; Diane E Cabelli; Michael J Maroney; Anne-Frances Miller; Miguel Teixeira; Joan Selverstone Valentine
Journal:  Chem Rev       Date:  2014-04-01       Impact factor: 60.622

3.  Aggregation propensities of superoxide dismutase G93 hotspot mutants mirror ALS clinical phenotypes.

Authors:  Ashley J Pratt; David S Shin; Gregory E Merz; Robert P Rambo; W Andrew Lancaster; Kevin N Dyer; Peter P Borbat; Farris L Poole; Michael W W Adams; Jack H Freed; Brian R Crane; John A Tainer; Elizabeth D Getzoff
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-14       Impact factor: 11.205

4.  Local unfolding of Cu, Zn superoxide dismutase monomer determines the morphology of fibrillar aggregates.

Authors:  Feng Ding; Yoshiaki Furukawa; Nobuyuki Nukina; Nikolay V Dokholyan
Journal:  J Mol Biol       Date:  2011-12-21       Impact factor: 5.469

5.  Probing the free energy landscapes of ALS disease mutants of SOD1 by NMR spectroscopy.

Authors:  Ashok Sekhar; Jessica A O Rumfeldt; Helen R Broom; Colleen M Doyle; Ryan E Sobering; Elizabeth M Meiering; Lewis E Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

6.  Enthalpic barriers dominate the folding and unfolding of the human Cu, Zn superoxide dismutase monomer.

Authors:  Can Kayatekin; Noah R Cohen; C Robert Matthews
Journal:  J Mol Biol       Date:  2012-09-18       Impact factor: 5.469

7.  Amyotrophic lateral sclerosis: update and new developments.

Authors:  Ashley J Pratt; Elizabeth D Getzoff; J Jefferson P Perry
Journal:  Degener Neurol Neuromuscul Dis       Date:  2012-02

8.  Calcium ions promote superoxide dismutase 1 (SOD1) aggregation into non-fibrillar amyloid: a link to toxic effects of calcium overload in amyotrophic lateral sclerosis (ALS)?

Authors:  Sónia S Leal; Isabel Cardoso; Joan S Valentine; Cláudio M Gomes
Journal:  J Biol Chem       Date:  2013-07-16       Impact factor: 5.157

9.  Protein charge ladders reveal that the net charge of ALS-linked superoxide dismutase can be different in sign and magnitude from predicted values.

Authors:  Yunhua Shi; Alireza Abdolvahabi; Bryan F Shaw
Journal:  Protein Sci       Date:  2014-08-07       Impact factor: 6.725

10.  Effects of maturation on the conformational free-energy landscape of SOD1.

Authors:  Robert M Culik; Ashok Sekhar; Jayashree Nagesh; Harmeen Deol; Jessica A O Rumfeldt; Elizabeth M Meiering; Lewis E Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.